Mainz Biomed B.V. (MYNZ) Social Stream
MAINZ BIOMED NV (MYNZ) Price Targets From Analysts
Use the tables below to see what analysts covering MAINZ BIOMED NV think about its future price and what recommendations they have for investors and traders.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2022-09-08 | 2 | $25 | $25 | $25 | $1.17 | 2036.75% |
| 2023-04-11 | 2 | $25 | $15 | $20 | $1.17 | 1609.4% |
| 2023-05-16 | 2 | $15 | $10 | $12.5 | $1.17 | 968.38% |
| 2023-06-01 | 2 | $12 | $10 | $11 | $1.17 | 840.17% |
| 2023-08-17 | 2 | $10 | $9 | $9.5 | $1.17 | 711.97% |
| 2023-08-18 | 2 | $9 | $7 | $8 | $1.17 | 583.76% |
| 2023-09-22 | 2 | $9 | $9 | $9 | $1.17 | 669.23% |
| 2023-11-20 | 2 | $9 | $5 | $7 | $1.17 | 498.29% |
| 2023-12-06 | 2 | $5 | $5 | $5 | $1.17 | 327.35% |
| NA | 1 | $NA | $NA | $NA | $1.17 | NA% |
The Trend in the Analyst Price Target
Over the past 110 days, MYNZ's average price target has gone down $3.
MYNZ reports an average of 230.12% for its upside potential over the past 42 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-04-11 | 2 | 25 | 15 | 20.0 | 5.87 | 240.72% |
| 2023-05-16 | 2 | 15 | 10 | 12.5 | 5.37 | 132.77% |
| 2023-08-17 | 2 | 10 | 9 | 9.5 | 2.93 | 224.23% |
| 2023-11-20 | 2 | 9 | 5 | 7.0 | 1.16 | 503.45% |
| 2023-12-06 | 2 | 5 | 5 | 5.0 | 1.10 | 354.55% |
MYNZ Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 2 | 1 | 0 | 1 | 0 | 0 | 2 |
The Trend in the Broker Recommendations
MYNZ's average broker recommendation rating worsened by 1 over the prior 18 months.
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for MYNZ as an investment opportunity.
- To contextualize these metrics, consider that out of all US stocks, MAINZ BIOMED NV's number of analysts covering the stock is higher than 25.38% of them.
- To contextualize these metrics, consider that out of all US stocks, MAINZ BIOMED NV's upside potential (average analyst target price relative to current price) is higher than 961.3% of them.
- In the context of Pharmaceutical Products stocks, MAINZ BIOMED NV's variance in analysts' estimates is lower than -24.13% of them.
- In the context of Healthcare stocks, MAINZ BIOMED NV's average analyst price target is higher than 221.1% of them.
In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to MAINZ BIOMED NV are DERM, BNOX, and NVCT.
View All Top Stocks by Price Target
Is MYNZ a Buy, Hold or Sell? See the POWR Ratings now!